Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI)

被引：18

作者：

Susan Yount

David Cella

Donald Banik

Talat Ashraf

Daniel Shevrin

机构：

[1] Ctr. on Outcomes Research/ Education, Evanston NW Healthcare/NW University, Evanston, IL 60201

[2] University of New England, College of Osteopathic Medicine, Biddeford, ME 04005

[3] Abbott Laboratories, Dept. R42J, Abbott Park, IL 60064-6124

[4] Evanston NW Healthcare/NW University, Evanston, IL 60201

来源：

Health and Quality of Life Outcomes | / 1卷 / 1期

关键词：

National Comprehensive Cancer Network; National Comprehensive Cancer Network; Advanced Prostate Cancer; Symptom Index; Hormone Refractory Prostate Cancer;

D O I：

10.1186/1477-7525-1-69

中图分类号：

学科分类号：

摘要：

Background: The objective of this study was to construct and validate a brief, clinically-relevant symptom index for advanced prostate cancer. Methods: Questions were extracted from a commonly-used multi-dimensional cancer quality of life instrument with prostate-specific items, the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Surveys of disease-related symptoms were presented to an international sample of 44 expert physicians. Each expert narrowed the list to no more than five of the most important symptoms or concerns to monitor when assessing the value of treatment for advanced prostate cancer. Symptoms/concerns endorsed at a frequency greater than chance probability (17%) were retained for the symptom index and called the FACT Advanced Prostate Symptom Index-8 (FAPSI-8): pain (three items), fatigue, weight loss, urinary difficulties (two items), and concern about the condition becoming worse. The FAPSI-8 was validated using data from a clinical trial of 288 men being treated for hormone refractory prostate cancer. Results: The FAPSI-8 showed good internal consistency (r = 0.67-0.80); association with existing FACT scales (e.g., FACT-P, Physical Well-being, Functional Well-being; r = 0.44 - 0.85, p < .0001), responsiveness to clinical change (Guyatt's Responsiveness statistic = 1.29), and ability to differentiate patients by performance status (p < .0001). A six-item alternate version of the FAPSI was also evaluated with comparable results. Conclusions: This project produced a reliable and valid list of the eight most important clinician-rated targets of drug therapy for advanced prostate cancer. These questions perform comparably to the longer derivative questionnaire. Examination of patient agreement with this priority list and the extent to which changes in these 8 targets are related to meaningful clinical benefit to the patient are important next steps for future research. © 2003 Yount et al; licensee BioMed Central Ltd.

引用

页数：12

共 45 条

[1]

Portenoy R.K., Thaler H.T., Kornblith A.B., McCarthy Lepore J., Friedlander-Klar H., Coyle N., Smart-Curley T., Kemeny N., Norton L., Hoskins W., Scher H., Symptom prevalence, characteristics and distress in a cancer population, Qual. Life Res., 3, pp. 183-189, (1994)

[2]

Coons S.J., Kaplan R.M., Assessing health-related quality of life: Application to drug therapy, Clin. Ther., 14, pp. 850-858, (1992)

[3]

Esper P., Hampton J.N., Smith D.C., Pienta K.J., Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer, Oncol. Nurs. Forum, 26, pp. 107-112, (1999)

[4]

Esper P., Mo F., Chodak G., Sinner M., Cella D., Pienta K.J., Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate Instrument, Urology, 50, pp. 920-928, (1997)

[5]

Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., deHaes J.C., The European Organization for Research and Treatment of Cancer QLQC30: A Quality-of-Life Instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst., 85, pp. 365-376, (1993)

[6]

Cella D.F., Tulsky D.S., Gray G., Sarfian B., Lloyd S., Linn E., Bonomi A., Silberman M., Yellen S.B., Winicour P., Brannon J., Eckberg K., Purl S., Blendowski C., Goodman M., Barnicle M., Stewart I., McHale M., Bonomi P., Kaplan E., Taylor S., Thomas C., Harris J., The Functional Assessment of Cancer Therapy (FACT) Scale: Development and validation of the general measure, J. Clin. Oncol., 11, pp. 570-579, (1993)

[7]

Cella D., Bonomi A.E., Measuring quality of life: 1995 update, Oncology, 9, pp. 47-60, (1995)

[8]

Schag C.A., Heinrich R.L., Development of a comprehensive quality of life measurement tool: CARES, Oncology (Huntingt), 4, pp. 135-138, (1990)

[9]

Bezjak A., Taylor K.M., Ng P., Macdonald K., DePetrillo A.D., Quality-of-life information and clinical practice: The oncologist's perspective, Cancer Prevention and Control, 2, pp. 230-235, (1998)

[10]

Deyo R.A., Patrick D.L., Barriers to the use of health status measures in clinical investigation, patient care, and policy research, Med. Care, 27, (1989)

← 1 2 3 4 5 →